BMGF – Gates Foundation  [to 26 Jan 2019]
No new digest content identified.
Bill & Melinda Gates Medical Research Institute    [to 26 Jan 2019]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.
CARB-X   [to 26 Jan 2019]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.
CEPI – Coalition for Epidemic Preparedness Innovations  [to 26 Jan 2019]
22 Jan 2019
World Economic Forum press conference: CEPI – Building a Global Coalition to End Epidemics
This press conference visited the progress made and previewed the years ahead for CEPI to finance and coordinate the development of new vaccines to prevent and contain infectious disease epidemics.
The press conference was hosted by Richard Hatchett (CEO, CEPI), and he was joined by Paul Stoffels (Vice Chair of the Executive Committee and Chief Scientific Officer), Jeremy Farrar (Director, Wellcome Trust), Ryan Morhard (Project Lead, Global Health and Healthcare Industries, World Economic Forum), and Lydia Ogden (Associate Vice-President, Global Enterprise Policy, MSD).
The conference streamed live at 1130 (GMT) on Jan 22, 2019.
22 Jan 2019
UK pledges £10 million to support CEPI
UK has committed funds to support CEPI’s mission to develop new life-saving vaccines to combat emerging infectious diseases and prevent future epidemics
EDCTP    [to 26 Jan 2019]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.
Emory Vaccine Center    [to 26 Jan 2019]
No new digest content identified.
European Medicines Agency  [to 26 Jan 2019]
News and press releases
No new digest content identified.
European Vaccine Initiative  [to 26 Jan 2019]
24 January 2019
Training in vaccine research and development
3rd Call for TRANSVAC Training Modules now advertised

Three PhD fellowships within MMVC programme
22 January 2019
The Multi-Stage Malaria Vaccine Consortium (MMVC) offers 3 PhD Fellowships in Malaria Research
FDA [to 26 Jan 2019]
No new digest content identified.
Fondation Merieux  [to 26 Jan 2019]
29 – 30 Jan 2019
Partner event
Global Vaccine Data Network meeting
Les Pensières Center for Global Health, Veyrier du Lac
Gavi [to 26 Jan 2019]
No new digest content identified.
GHIT Fund   [to 26 Jan 2019]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.
Global Fund  [to 26 Jan 2019]
25 January 2019
Measuring and Reporting Results
Smart, effective health investments through the Global Fund partnership have saved more than 27 million lives, and that remarkable success against the world’s deadliest infectious diseases could only be achieved by the collaborative efforts of many partners. We welcome all discussion and ideas on how best to measure and report the results of interventions in global health. Given the imperative to optimize impact from constrained resources – whether domestic or external – it is vital that we measure and communicate what’s working and what isn’t. Donors and domestic taxpayers want to know their money is being used to maximum effect. Implementers and technical partners need to know what to expand and what to modify.
Hilleman Laboratories   [to 26 Jan 2019]
No new digest content identified.
Human Vaccines Project   [to 26 Jan 2019]
January 24, 2019
Welcoming Adaptive Biotechnologies’ Harlan Robins to Scientific Steering Committee
The Human Vaccines Project welcomes Harlan Robins, Ph.D., head of innovation and co-founder at Adaptive Biotechnologies, to the Project’s Scientific Steering Committee…
IAVI  [to 26 Jan 2019]
No new digest content identified.
No new digest content identified.
IVAC  [to 26 Jan 2019]
No new digest content identified.
IVI   [to 26 Jan 2019]
IVI News & Announcements
No new digest content identified.
JEE Alliance  [to 26 Jan 2019]
No new digest content identified.
MSF/Médecins Sans Frontières  [to 26 Jan 2019]
Selected News; Project Updates, Reports
The challenge of filling gaps in the legs of Gaza’s wounded
Project Update 24 Jan 2019
Refugees returned to overcrowded Libyan detention centres
Project Update 23 Jan 2019
Mental health
Displaced and distressed: people’s mental health in East Africa
Project Update 22 Jan 2019
NIH  [to 26 Jan 2019]
January 25, 2019
Investigational monoclonal antibody to treat Ebola is safe in adults
— Early-stage trial results show promise.
[See Milestones above for detail]
Wednesday, January 23, 2019
New fellowship program will support the next generation of African scientific leaders
NIH collaborates with African Academy of Sciences and Bill & Melinda Gates Foundation.
Dr. Michael Otto of NIH’s National Institute of Allergy and Infectious Diseases is hosting APTI fellow Dr. Nana Amissah of Ghana, who is studying Staphylococcus aureus.FIC/NIH
Ten African scientists have been selected for training at the National Institutes of Health as part of a new fellowship program to build research capacity in African countries and develop ongoing scientific partnerships. NIH, the African Academy of Sciences, and the Bill & Melinda Gates Foundation are collaborating to establish the African Postdoctoral Training Initiative.
The inaugural cohort will assume their positions in NIH host labs in early 2019. NIH will provide two years of training under principal investigators who share the fellows’ research interests. The African scientists will then return to their home institutions and receive two years of support to continue the research and establish themselves as independent investigators. NIH and the Gates Foundation are together providing about $4 million for the program…

Temperature-stable experimental tuberculosis vaccine enters clinical testing
January 23, 2019 — Tuberculosis remains the leading infectious cause of death worldwide.
Vaccinations have begun in a Phase 1 human clinical trial testing a freeze-dried, temperature-stable formulation of an experimental tuberculosis (TB) vaccine candidate. The trial is being conducted at the Saint Louis University School of Medicine Center for Vaccine Development and will enroll as many as 48 healthy adult volunteers aged 18 to 55 years. The experimental vaccine, called ID93, was developed by scientists at the Infectious Disease Research Institute (IDRI) in Seattle. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is supporting the trial through a contract to IDRI.
ID93 is a recombinant vaccine candidate made from four proteins of Mycobacterium tuberculosis (the bacterium that causes TB). Many vaccines require a temperature-controlled system during transport, which can be costly and logistically challenging. Freeze-dried powder vaccines can be distributed at a cheaper cost to remote, low-resource settings. The powder formulations are mixed with sterile water for administering with a needle and syringe…

Dengue immunity may be protective against symptomatic Zika, study finds
January 22, 2019 — Zika virus and dengue virus are both transmitted by Aedes aegypti mosquitoes and cause similar symptoms.
PATH  [to 26 Jan 2019]
No new digest content identified.
Sabin Vaccine Institute  [to 26 Jan 2019]
No new digest content identified.
UNAIDS [to 26 Jan 2019]
Selected Press Releases/Reports/Statements
No new digest content identified.
UNICEF  [to 26 Jan 2019]
Selected Press Releases/Reports/Statements
UNICEF Statement on the situation in Venezuela

Press release
More than 145,000 Rohingya refugee children return to school in Bangladesh refugee camps as new school year starts

UNICEF statement on the impact of the ongoing turmoil and economic crisis on children in Sudan
Statement attributable to Geert Cappelaere, UNICEF Regional Director for the Middle East and North Africa

Press release
Vital protection for refugee and migrant children making perilous sea journeys to Europe urgently needed – UNICEF
In first two weeks of 2019, more than 400 uprooted children reached European shores amid freezing temperatures and rough waters
Vaccine Confidence Project  [to 26 Jan 2019]
No new digest content identified.
Vaccine Education Center – Children’s Hospital of Philadelphia  [to 26 Jan 2019]
No new digest content identified.
Wellcome Trust  [to 26 Jan 2019]
Explainer | 22 January 2019
CEPI can develop new vaccines to fight epidemics – but it needs global funding
Developing new vaccines is challenging, costly and complex. The Coalition for Epidemic Preparedness Innovation (CEPI) is a new model for funding vaccine development which aims to change this.

News | 22 January 2019
Acting Director of Science announced
Mike Turner has been appointed Acting Director of Wellcome’s Science Division.
The Wistar Institute   [to 26 Jan 2019]
Press Release    Jan. 24, 2019
Induction of Potent Anticancer Immunity Through Rapid Tumor Antigen Identification and Conversion to Personalized Synthetic DNA Vaccines
Custom synthetic DNA vaccines elicit efficacious killer T-cell responses that significantly delay tumor progression in lung and ovarian cancer preclinical models.
World Organisation for Animal Health (OIE)   [to 26 Jan 2019]
No new digest content identified.




BIO    [to 26 Jan 2019]
No new digest content identified.
DCVMN – Developing Country Vaccine Manufacturers Network  [to 26 Jan 2019]
No new digest content identified.
IFPMA   [to 26 Jan 2019]
No new digest content identified.
PhRMA    [to 26 Jan 2019]
No new digest content identified.